acute or chronic unproductive cough of any origin; medical preparation for bronchoscopic or bronchographic examination.
prenoxdiazine hydrochloride 100 mg;
Libexin pharmachologic effect
Prenoxdiazine is a peripheral antitussive agent.
The drug Libeksin blocks the peripheral links of the cough reflex due to the following effects:
– local anesthetic effect, which reduces irritability of the peripheral sensitive (cough) receptors of the respiratory tract;
– bronchodilatory action, due to which there is a suppression of stretch receptors involved in the cough reflex;
– a slight decrease in the activity of the respiratory center (without respiratory depression). The antitussive effect of the drug is approximately equal to that of codeine.
Prenoxdiazine is not addictive and drug-dependent. In chronic bronchitis, the anti-inflammatory effect of prenoxdiazine has been noted. Prenoxdiazine does not affect the function of the central nervous system, with the exception of a possible indirect anxiolytic effect.
Unproductive cough of any origin:
catarrh of the upper respiratory tract, influenza, acute and chronic bronchitis, pneumonia, emphysema;
nocturnal cough in patients with heart failure;
preparation of patients for bronchoscopic or bronchographic examination.
hypersensitivity to the drug;
diseases associated with abundant bronchial secretion;
condition after inhalation anesthesia;
galactose intolerance, lactase deficiency or glucose-galactose malabsorption.
With care: children’s age.
Allergic reactions: rarely – skin rash; angioedema; unknown frequency – bronchospasm.
From the gastrointestinal tract: rarely – dry mouth or throat; anesthesia (temporary numbness and loss of sensitivity) of the oral mucosa; often – stomach pain; constipation; nausea.
From the side of the nervous system (when using the drug in high doses): unknown frequency – mild sedation; fatigue.
It is not recommended to combine the drug with mucolytic and expectorant drugs, because it can obstruct the secretion of phlegm, which is liquefied by the latter.
There is no preclinical or clinical data on interactions with other drugs.